Axsome Therapeutics Inc annual operating income for fiscal TTM was -$189 million, a decrease of 11.8% from -$169 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($189M) | ($169M) | ($281M) | ($232M) | ($180M) | ($125M) | ($99M) | ($67M) | ($33M) | ($27M) | ($28M) | ($9M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($51M) | ($63M) | ($29M) | ($46M) | ($37M) | ($57M) | ($73M) | ($63M) | ($78M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More AXSM metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All AXSM financial statements → Interactive AXSM charts →
About TickerBase · Data methodology & sources · Privacy · Terms